Connect with us

Technology

SOPHiA GENETICS and Genomenon Collaborate to Streamline Genetic Research

Published

on

The companies expand partnership to enhance genetic variant interpretation for cancers and rare diseases

BOSTON and ROLLE, Switzerland , Nov. 6, 2024 /PRNewswire-PRWeb/ — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, today announced the next step in the partnership between the Company and Genomenon, a leading genomic intelligence company, to support better, data-driven outcomes in the rare disease and oncology fields. The two companies have expanded the integration of Genomenon’s Mastermind® Genomic Intelligence Platform into SOPHiA GENETICS’ Alamut™ Visual Plus, to empower researchers and clinical geneticists with a solution that helps accelerate variant interpretation for rare disorders.

Time is crucial in gathering actionable insights for rare diseases and cancers due to the complexity and unknown elements of their genetic underpinnings. Identifying these variants often involves navigating limited literature and sparse data, as many rare disorders lack comprehensive studies. Delays in finding relevant information can hinder accurate analysis and interpretation of genomic variants. Many rare conditions have no cure, and easy access to relevant, comprehensive and well-organized information can help accelerate insights and health decisions.

Alamut™ Visual Plus is an advanced decision-support tool for the exploration, annotation, and interpretation of genetic variants from next-generation sequencing (NGS) data. Genomenon’s Mastermind® Genomic Intelligence Platform provides comprehensive curated evidence for genomic data, as well an indexed content from more than 10 million full-text articles. The integration of the two tools significantly enhances variant curation and interpretation by connecting the Alamut™ Visual Plus comprehensive, full genome browser for variant interpretation to a vast library of scientific research, offering critical insights even for rare variants with limited existing research. This partnership will prove especially valuable in such cases where findings from only a single study globally might be available that hold the key to understanding a variant’s pathogenicity. By offering immediate access to a broad spectrum of indexed data and curated genomic insights, researchers and clinicians can more efficiently assess the pathogenicity of variants, enabling them to make informed decisions with greater confidence.

“We are excited to expand our work with Genomenon and provide our customers the opportunity to access world-class tools like Mastermind® through our technology platform.” said Ross Muken, President, SOPHiA GENETICS. “This partnership simultaneously benefits our customers, who will gain a more comprehensive understanding of detected variants in a seamless, single platform, while providing Genomenon the opportunity to broaden its reach through our unmatched global network.”

“Collaborating with SOPHiA GENETICS allows us to provide geneticists and researchers with the most comprehensive and up-to-date genomic research available as they review patient data in Alamut,” said Mike Klein, CEO of Genomenon. “The links to Mastermind® from Alamut will put curated genomic data and the most recent research on every variant at the fingertips of clinicians assure patient diagnoses are informed by the most recent scientific findings in a single, complete workflow.”

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn.

About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.

About Genomenon
Genomenon is a leading genomic intelligence company transforming patient care by uncovering the genomic drivers of genetic disease and cancer. By combining the power of AI built on the world’s premier genomic data set with genomic expertise, the company simplifies complex genetic data into actionable insights. Genomenon’s integrated software, data, and services solutions empower clients with advanced patient diagnosis and precision medicine development. For more information, visit GENOMENON.COM.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

SOPHiA GENETICS Media Contact:
Kelly Katapodis
media@sophiagenetics.com

Genomenon Media Contact:
Colleen McMillen
cmcmillen@genomenon.com

Media Contact

Colleen McMillen, https://www.genomenon.com, 9173449360, cmcmillen@genomenon.com, https://www.genomenon.com

Twitter

View original content to download multimedia:https://www.prweb.com/releases/sophia-genetics-and-genomenon-collaborate-to-streamline-genetic-research-302297017.html

SOURCE Genomenon

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Avantor® Appoints Dame Louise Makin, DBE, Ph.D., to its Board of Directors

Published

on

By

RADNOR, Pa., Nov. 6, 2024 /PRNewswire/ — Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that the Avantor Board of Directors has appointed Dame Louise Makin, DBE, Ph.D., as a director with an initial term expiring at Avantor’s 2025 Annual Meeting of Stockholders. The appointment of Dame Louise as an independent director fills a vacant board seat.

Dame Louise brings a wealth of leadership and industry experience to the Avantor Board. She served as Chief Executive Officer of BTG plc, an international specialist healthcare company, for 15 years and led their transformation through organic growth and acquisitions. The company was acquired by Boston Scientific in 2019. Earlier in her career, she held several leadership positions at Baxter Healthcare, most recently as President of Biopharmaceuticals Europe.

“Dame Louise has a proven track record of success in the life sciences industry, and we are excited to welcome her to the Avantor Board of Directors,” said Jonathan Peacock, Chairman of the Avantor Board. “Her addition further demonstrates Avantor’s commitment to ensuring we have a diverse Board, with the right mix of skillsets and experience to drive innovation across our portfolio, advance our mission, and create long-term shareholder value.”

“It is an honor to join the Avantor Board of Directors, and I look forward to working closely with the board and executive team to further strengthen the company’s position as a leader in the life sciences and advanced technologies industries,” said Dame Louise. “Avantor’s global reach, innovative products, and services uniquely position it to drive advancements at every stage of the scientific journey and deliver differentiated value to its many stakeholders.”

“Dame Louise is an excellent addition to our Board. I welcome her insights and expertise as we continue to execute our strategic plan to drive long-term growth and value creation,” said Michael Stubblefield, Avantor President and Chief Executive Officer.

Dame Louise currently serves as non-executive chair of the Halma plc Board of Directors and has served as a Non-Executive Director on the Boards of Premier Foods plc, Intertek Group plc, Woodford Patient Capital Trust, Atotech Ltd., and Theramex Ltd. She was also a Trustee of The Outward Bound Trust for 10 years and Chair of the 1851 Trust for five years.

Dame Louise is an Honorary Fellow of St John’s College, Cambridge. She holds both a master’s degree in natural sciences and a Ph.D. in material sciences from the University of Cambridge and earned an MBA from The Open University in Milton Keynes, England. She became a Dame Commander of the Order of the British Empire in 2014.

About Avantor
Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedInX (Twitter) and Facebook.

Global Media Contact
Eric Van Zanten
Head of External Communications
Avantor
610-529-6219
Eric.VanZanten@avantorsciences.com

Investor Relations Contact
Christina Jones
Vice President, Investor Relations
Avantor
805-617-5297
Christina.Jones@avantorsciences.com

 

View original content:https://www.prnewswire.com/news-releases/avantor-appoints-dame-louise-makin-dbe-phd-to-its-board-of-directors-302297011.html

SOURCE Avantor and Financial News

Continue Reading

Technology

Phoenix IB Advises Spray Products in Successful $40 Million Refinancing

Published

on

By

PHILADELPHIA, Nov. 6, 2024 /PRNewswire/ — Phoenix IB®, a part of J.S. Held, a leading middle market special situations investment bank and independent licensed broker-dealer under federal and state securities law (CRD#: 132710/SEC#: 8-66628), acted as the exclusive investment banker to its long-term client, Spray Products Corporation, in arranging, structuring, and negotiating a $40 million loan package with Legacy Corporate Lending. 

J.S. Held subsidiary Phoenix IB closes refinancing with Legacy Corporate Lending.

“Phoenix IB is delighted with the credit package we were able to arrange for Spray Products,” noted Michael Jacoby, a Senior Managing Director at Phoenix IB. “Not surprisingly, there was a lot of interest from a variety of lenders, both regulated and non-regulated. The Legacy team spent the time to understand the Company and its business plan, and tailored a solution that fit Spray’s needs and will provide the necessary support for years to come.”

Spray Products is a leading custom contract manufacturer of aerosol and liquid consumer products. Proceeds from the financing will be utilized to refinance the Company’s existing credit facilities and fund additional working capital to finance its continued growth and capital expenditures. Peter Bastian, Executive Vice President of Spray Products LLC, shares, “We could not be more pleased with the closing of our new financing with Legacy Corporate Lending and the guidance we received throughout the transaction from Phoenix IB. The Phoenix team was able to successfully communicate our story, and through our new facility with Legacy, we are confident we have partnered with a firm that shares our values and is excited to support Spray’s next phase of growth.” 

Legacy Corporate Lending LLC, in alliance with Bain Capital Credit, L.P., specializes in providing revolving credit facilities and term loans to businesses across diverse industries. The firm aims to facilitate access to capital for companies seeking alternatives to traditional bank lending or the syndicated lending market.

“We were extremely impressed with the refinancing process that Phoenix IB led for Spray Products,” said Clark Griffith, CEO of Legacy Corporate Lending, LLC. “The professionalism and fairness shown by Steven Warsaw, Michael Jacoby, and the team was refreshing to experience and appreciated in this competitive market. Our process was easy to navigate given the quality of the information, their responsiveness to questions, and the approach they took in understanding the best borrower/lender fit.”

Doug Greer, Spray Products Chief Financial Officer, adds, “Michael Jacoby, Steven Warsaw, and their team spent considerable time to understand the intricacies of our business and worked closely with us to develop a financing structure that meets our needs for the next several years. We believe that we will continue to see the benefits of their collaboration with our business well beyond our engagement.”

Across a broad spectrum of client types, from start-ups in an early stage with exciting growth potential to a mature company amid a corporate turnaround, Phoenix IB capital raising services are designed to provide tailored financing solutions across the capital structure, particularly for clients faced with complex growth or funding situations. “At Phoenix IB, every transaction we close reflects our precision, perseverance, and partnership with our clients,” shares Phoenix IB Managing Director Steven C. Warsaw. Mr. Warsaw continues, “The robust interest in financing Spray Products created a highly competitive process, and we are very pleased to have selected the loan package provided by Legacy, which we feel is best positioned to provide needed flexibility as Spray facilitates its next chapter of growth.”

About Phoenix IB

Phoenix IB is a boutique, special situations-oriented investment bank providing seamless investment banking solutions, including M&A advisory, complex restructurings, and capital placements. Phoenix IB is a US registered broker-dealer and member of FINRA and SIPC.

As a part of J.S. Held, Phoenix works alongside more than 1500 professionals globally and assists clients – corporations, insurers, law firms, governments, and institutional investors.

J.S. Held is a global consulting firm that combines technical, scientific, financial, and strategic expertise to advise clients seeking to realize value and mitigate risk. Our professionals serve as trusted advisors to organizations facing high-stakes events demanding urgent attention, staunch integrity, clear-cut analysis, and an understanding of both tangible and intangible assets. The firm provides a comprehensive suite of services, products, and data that enable clients to navigate complex, contentious, and often catastrophic situations.

J.S. Held professionals serve organizations across six continents, including 81% of the Global 200 Law Firms, 70% of the Forbes Top 20 Insurance Companies (85% of the NAIC Top 50 Property & Casualty Insurers), and 65% of the Fortune 100 Companies.

J.S. Held, its affiliates and subsidiaries are not certified public accounting firm(s) and do not provide audit, attest, or any other public accounting services. J.S. Held, its affiliates and subsidiaries are not law firms and do not provide legal advice. Securities offered through PM Securities, LLC, d/b/a Phoenix IB, a part of J.S. Held, member FINRA/ SIPC or Ocean Tomo Investment Group, LLC, a part of J.S. Held, member FINRA/ SIPC. All rights reserved.

Media Contact

Kristi L. Stathis, J.S. Held, +1 773 294 4360, Kristi.Stathis@jsheld.com, JSHeld.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/phoenix-ib-advises-spray-products-in-successful-40-million-refinancing-302297143.html

SOURCE Phoenix IB, a part of J.S. Held

Continue Reading

Technology

Grovara’s Safe B2B CPG Global Trading Platform Expands Product Offering Into Eyewear, Will Add 10-Plus Complementary Verticals By End Of 2025

Published

on

By

PHILADELPHIA, Nov. 6, 2024 /PRNewswire/ — Grovara, the safe, all-in-one platform streamlining global trade for the Business-to-Business (B2B) Consumer Packaged Goods (CPG) industry, is expanding the offerings on its online marketplace beyond food and beverage beginning with the rapidly growing eyewear market.

The global eyewear market is projected to grow by more than 18% through 2029, presenting a tremendous growth opportunity via higher margins and increasing online sales. Grovara is now selling Popticals, collapsible sunglasses for active lifestyles featuring Italian craftsmanship and superior lens technology. In the coming weeks there are plans to add additional eyewear brands, which can now tap Grovara’s technology to simplify their typical sales transaction from three weeks to three clicks. 

“The potential for Grovara’s platform is infinite, and expanding into the eyewear vertical is a great step forward as we ramp up and evolve our SaaS technology offering,” says Grovara CEO Peter Groverman. “Whether you’re selling a kombucha or carousel of sunglasses, the transaction process is the same and Grovara’s platform handles the full process.”

Popticals deliver an unequaled combination of quality, performance, and convenience. The brand boasts an innovative nylon-based lens technology, plus a patented micro-rail system that allows its glasses to collapse down for uniquely easy storage.

“We are excited to join Grovara’s growing platform and bring our unique product within the premium sunglasses market to a global audience,” says Gary DiSalvo, Owner and CEO of Popticals. “This partnership allows us to share our commitment to quality and innovation with more people. Additionally, it aligns with Grovara’s mission of making high-quality, complementary products easily accessible to businesses around the world.”

Over the last decade, Grovara has become a leader in the natural food and beverage sector by growing the global profile of some of the most well-known brands in the world – like GT’s Kombucha, True Citrus, and Honey Stinger — and helping them break into new markets. Grovara’s expansion into other complementary verticals will include 10 new product categories over the next 12 months, including beauty, pets, home goods, and alcohol.

Grovara’s CPG expansion is powered by its partnership with Accelerate360, an omni-commerce sales, media, and distribution company that propels promising brands by supercharging affinity and availability. Accelerate360 recently launched 50 models of premium reader eyeglasses on Grovara with many more categories and brands on the way.

“We are excited to partner with Grovara as they establish new product categories and provide expanded opportunities for entrepreneurs and challenger brands” says Accelerate360’s Sam Roberts, VP of eCommerce – Pure Play & Omni-Channel Retail.

Those CPG brands interested in joining Grovara’s platform can reach out for a demo of its SaaS technology here.

Contact:
J.A. Petrucci
215-203-2227
385927@email4pr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/grovaras-safe-b2b-cpg-global-trading-platform-expands-product-offering-into-eyewear-will-add-10-plus-complementary-verticals-by-end-of-2025-302297505.html

SOURCE Grovara

Continue Reading

Trending